Serina Therapeutics, Inc. (SER)
| Market Cap | 53.09M +3.4% |
| Revenue (ttm) | n/a +132.1% |
| Net Income | -23.93M |
| EPS | -1.93 |
| Shares Out | 25.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,447 |
| Open | 2.140 |
| Previous Close | 2.140 |
| Day's Range | 2.140 - 2.140 |
| 52-Week Range | 1.220 - 5.830 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 9.50 (+354.55%) |
| Est. Earnings | Nov 12, 2026 |
About SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it ... [Read more]
Financial Performance
In 2025, Serina Therapeutics's revenue was $130,000, an increase of 132.14% compared to the previous year's $56,000. Losses were -$19.44 million, 74.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SER stock is "Strong Buy." The 12-month stock price target is $9.5, which is an increase of 354.55% from the latest price.
News
Serina Therapeutics Transcript: Status update
SER-252, a novel long-acting therapy for advanced Parkinson's, showed promising safety and pharmacokinetics in early clinical data, supporting further dose escalation. The company is well-funded, with strong insider backing, and is advancing a pipeline of POZ-enabled CNS therapies, including the undisclosed SER-290. Key regulatory milestones and data readouts are expected through 2027.
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"
Featuring Serina Therapeutics' CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson's disease with no major clinical advances in 50+ years Meet with Serina's CEO ...
Serina Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
SER-252, a novel therapy for advanced Parkinson's, has completed cohort one in its phase I-B study and advanced to cohort two, with top-line data expected in early 2027. The product targets a large unmet need with a user-friendly, twice-weekly on-body system, aiming to improve adoption over current device-based therapies.
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Pla...
Serina Therapeutics Slides: Investor presentation
Serina Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2
- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose eval...
Serina Therapeutics files to sell 12.5M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 12.5M shares of common stock. The company is not selling any…
Serina Therapeutics Registration statement: Registration filing
Serina Therapeutics filed a registration statement on August 24, 2026, providing details about a securities offering with the SEC.
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform...
Serina Therapeutics Quarterly report: Q2 2026
Serina Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Serina Therapeutics Earnings release: Q2 2026
Serina Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Pl...
Serina Therapeutics completes enrollment and dosing in Parkinson’s trial
Serina Therapeutics (SER) completed enrollment and dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease. All eight ...
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease
- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety...
Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board
Serina Therapeutics (SER) announced the appointment of Farrell Simon to its board of directors, effective immediately. Simon will also serve on the board’s audit and compensation committees. He curren...
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Pla...
Serina completes sentinel dosing in Cohort 1 of Phase 1b trial of SER-252
Serina Therapeutics (SER) announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease...
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
HUNTSVILLE, Ala., July 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Pl...
Serina Therapeutics Slides: Investor presentation
Serina Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Serina Therapeutics initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated coverage of Serina Therapeutics (SER) with a Buy rating and $8 price target Serina is a clinical stage biotechnology company developing therapeutics designed to e...
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem , a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE Ameri...
Serina Therapeutics Transcript: AGM 2026
The meeting covered eight proposals, all of which were approved, including director elections, share increase, incentive plan amendment, and auditor ratification. No questions were raised by stockholders, and final voting results will be filed with the SEC.
Serina Therapeutics files to sell 16.45M shares of common stock for holders
16:01 EDT Serina Therapeutics (SER) files to sell 16.45M shares of common stock for holders
Serina Therapeutics Registration statement: Registration filing
Serina Therapeutics filed a registration statement on May 22, 2026, providing details about a securities offering with the SEC.
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 -